PMID: 1893005Feb 1, 1991

Acetylation polymorphism in lung cancer

Anales de medicina interna : organo oficial de la Sociedad Española de Medicina Interna
J M Laredo QuesadaG Pérez-Manga


The acetylation phenotype was determined, by means of sulfamethazine measurement, in 87 patients (83 male) with confirmed bronchogenic carcinoma and in 93 healthy control patients (41 male) of equal ages. 48 patients and 54 controls were classified as being "slow acetylators" (Ch2 n.s.) When the persons were individually analysed by phenotype, it was confirmed that the patients showed a significantly lower rate of acetylated sulfamethazine than the control group (p less than 0.02), owing to the poor acetylation of patients with small-cell lung cancer. This difference should be confirmed by more detailed pharmacokinetic studies before regarding it as a possible interference of paraneoplasic type. The polymorphism acetylator cannot be considered a genetic marker related to the risk of having lung cancer.

Related Concepts

Arylamine N-Acetyltransferase
Bronchogenic Carcinoma
Malignant Neoplasm of Lung
Genetic Polymorphism

Related Feeds

Carcinoma, Bronchogenic

Bronchogenic Carcinoma is a malignant lung cancer arising in the epithelium of the bronchus or bronchiole. Discover the latest research on Bronchogenic Carcinoma here.

Related Papers

European Journal of Clinical Pharmacology
J M LaderoJ J Muñoz
L C Jiménez-NietoA Robledo
Drug Metabolism and Disposition : the Biological Fate of Chemicals
W W WeberG S Drummond
© 2021 Meta ULC. All rights reserved